DNMT1 and lymphoma: A patient with AITL and a patient with CLL had loss of function TET2 mutations, which indicates sensitivity towards DNMT inhibitors such as Decitabine or Azacitidine, which both are tested in clinical trials for treatment in different lymphoma sub types [34].